News for NFL Biosciences (ALNFL.PA)

Published at

Sep 26, 2024 7:00 PM

by globenewswire.com

mixed

mixed

Global Nicotine Replacement Therapy Market is Predicted to Exhibit Remarkable Growth at a CAGR of ~7% by 2030 | DelveInsight

The nicotine replacement therapy market is mainly driven by increased smoking cessation programs, heightened health awareness, and the rising incidence of...

OSUKF OMER JNJ DJNJ3.BA DJNJ2.BA 0KBU.L PFED.BA PFE.MX PFE.DE PFE ALNFL.PA

Read more →
Published at

May 23, 2024 12:29 AM

by marketscreener.com

negative

negative

NFL BIOSCIENCES : RETOUR POSITIF DE LA FDA SUR LA DEMANDE DE PRE IND POUR NFL 301 DÉDIÉ À LA RÉDUCTION DE LA CONSOMMATION D’ALCOOL

NFL BIOSCIENCES : RETOUR POSITIF DE LA FDA SUR LA DEMANDE DE PRE-IND POUR NFL-301 DÉDIÉ À LA RÉDUCTION DE LA CONSOMMATION D'ALCOOL 21 May...

ALNFL.PA

Read more →
Published at

May 21, 2024 8:09 AM

by marketscreener.com

positive

positive

NFL BIOSCIENCES: POSITIVE FDA RESPONSE FOLLOWING THE PRE IND APPLICATION FOR NFL 301 FOR REDUCING ALCOHOL CONSUMPTION

NFL BIOSCIENCES: POSITIVE FDA RESPONSE FOLLOWING THE PRE-IND APPLICATION FOR NFL-301 FOR REDUCING ALCOHOL CONSUMPTION 21 May 2024 08:00 CEST ...

ALNFL.PA

Read more →
Published at

Apr 12, 2024 12:29 PM

by marketscreener.com

positive

positive

NFL Biosciences: successful capital increase -April 12, 2024 at 06:29 am EDT

NFL Biosciences announced on Friday that it had successfully completed its capital increase for over three million euros.The biopharmaceutical company, which develops botanical medicines to treat...

ALNFL.PA

Read more →
Published at

Apr 12, 2024 7:47 AM

by marketscreener.com

positive

positive

NFL Biosciences : Successful capital increase for NFL Biosciences with over €3 million raised -April 12, 2024 at 01:47 am EDT

Successful capital increase for NFL Biosciences with over €3 million raised 12 Apr 2024 07:45 CEST ...

ALNFL.PA

Read more →
Published at

Apr 2, 2024 8:09 AM

by marketscreener.com

negative

negative

NFL BIOSCIENCES : VALORISE SES RÉSULTATS D’ÉTUDES AUPRÈS DE LA COMMUNAUTÉ SCIENTIFIQUE ET PHARMACEUTIQUE -April 02, 2024 at 02:09 am EDT

NFL BIOSCIENCES VALORISE SES RÉSULTATS D'ÉTUDES AUPRÈS DE LA COMMUNAUTÉ SCIENTIFIQUE ET PHARMACEUTIQUE 02 Apr 2024 08:00 CEST ...

ALNFL.PA

Read more →
Published at

Mar 29, 2024 5:52 PM

by marketscreener.com

negative

negative

NFL BIOSCIENCES : ACTIVITÉS & RÉSULTATS ANNUELS 2023 -March 29, 2024 at 12:52 pm EDT

NFL BIOSCIENCES : ACTIVITÉS & RÉSULTATS ANNUELS 2023 29 Mar 2024 17:45 CET Subscribe ...

ALNFL.PA

Read more →
Published at

Oct 5, 2023 7:12 PM

by marketscreener.com

positive

positive

NFL BIOSCIENCES: 2023 FIRST-HALF BUSINESS AND EARNINGS UPDATE -October 05, 2023 at 01:12 pm EDT

- 39,025 Corporate income tax Net income Shareholders' equity 1,907,772 2,216,127 843,996 Intangible assets 122,785 139,577 135,784 Liabilities - Of which financial liabilities - Of which...

ALNFL.PA

Read more →
Published at

Sep 25, 2023 9:27 AM

by marketscreener.com

neutral

neutral

NFL Biosciences : Promising results of the PRECESTO clinical trial revealing a prolonged effect for NFL-101 and modification of the strategy for communicating the CESTO II study results -September 25,

• • • • • Attachments Original Link ...

ALNFL.PA

Read more →
Published at

Sep 25, 2023 8:19 AM

by marketscreener.com

positive

positive

NFL BIOSCIENCES: PROMISING RESULTS OF THE PRECESTO CLINICAL TRIAL REVEALING A PROLONGED EFFECT FOR NFL-101 AND MODIFICATION OF THE STRATEGY FOR COMMUNICATING THE CESTO II STUDY RESULTS -September 25,

NFL BIOSCIENCES: PROMISING RESULTS OF THE PRECESTO CLINICAL TRIAL REVEALING A PROLONGED EFFECT FOR NFL-101 AND MODIFICATION OF THE STRATEGY FOR COMMUNICATING THE CESTO II STUDY...

ALNFL.PA

Read more →